Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

3.6K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
3.6K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

64.3K
Overview
64.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.5K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

428
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
428

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal multiomics profiling of extracorporeal cross-circulation with pig liver xenografts in human decedents.

Nature medicine·2026
Same author

A Decade of Progress in Uterus Transplantation in the United States: Results From the World Transplant Congress 2025.

Transplantation·2026
Same author

International Forum on Visceral Myopathy 2024: Advances in the Knowledge of the Disease.

Neurogastroenterology and motility·2026
Same author

Inhibition of NFAT after human uterus transplant promotes loss of tissue-resident NK cells and attendant pregnancy complications.

Science translational medicine·2026
Same author

Graft-derived VWF drives platelet activation and thrombocytopenia during porcine liver xenotransplantation to brain-dead human recipients.

The Journal of clinical investigation·2026
Same author

Simultaneous quantification of native human and transgenic porcine liver function in a decedent model of extracorporeal cross-circulation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026

Related Experiment Video

Updated: Apr 27, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.1K

Immunosuppression: trends and tolerance?

Paige M Porrett1, Sohaib K Hashmi2, Abraham Shaked3

  • 1Division of Liver Transplantation, Department of Surgery, The University of Pennsylvania, 3400 Spruce Street, One Founders Pavilion, Philadelphia, PA 19104, USA.

Clinics in Liver Disease
|July 15, 2014
PubMed
Summary

Liver transplant recipients benefit from immunosuppression, but long-term drug use causes significant health issues. Research explores minimizing immunosuppression and using biomarkers to guide treatment for better patient outcomes.

Keywords:
BiomarkersImmunosuppressionMinimizationTolerance

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

13.8K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

15.5K

Related Experiment Videos

Last Updated: Apr 27, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.1K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

13.8K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

15.5K

Area of Science:

  • Transplantation immunology
  • Pharmacology
  • Clinical medicine

Background:

  • Pharmacologic immunosuppression has led to excellent liver transplant outcomes.
  • Long-term immunosuppression is associated with increased patient morbidity and mortality.
  • Current protocols rely heavily on these drugs, necessitating a review of alternatives.

Purpose of the Study:

  • To summarize current immunosuppression agents in liver transplantation.
  • To discuss the trend towards minimizing or eliminating immunosuppressive agents.
  • To review data supporting immunosuppression minimization and tolerance induction.
  • To examine the role of biomarkers in guiding immunosuppression management.

Main Methods:

  • Review of contemporary liver transplantation immunosuppression protocols.
  • Analysis of recently published data on immunosuppression minimization strategies.
  • Evaluation of studies investigating biomarkers for immunosuppression guidance.
  • Synthesis of evidence regarding tolerance induction in transplant recipients.

Main Results:

  • Advances in immunosuppression have improved initial transplant success.
  • Long-term use of these drugs presents a significant clinical challenge.
  • Emerging data supports the feasibility of reducing or stopping immunosuppression.
  • Biomarker research shows promise for personalized immunosuppression management.

Conclusions:

  • Minimizing immunosuppression in liver transplant recipients is a growing trend.
  • Future strategies may involve tolerance induction and biomarker-guided therapy.
  • Reducing drug burden is crucial for improving long-term patient survival and quality of life.